Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Net Income towards Common Stockholders: 2016-2024

Historic Net Income towards Common Stockholders for Akebia Therapeutics (AKBA) over the last 9 years, with Dec 2024 value amounting to -$69.4 million.

  • Akebia Therapeutics' Net Income towards Common Stockholders rose 102.69% to $540,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.9 million, marking a year-over-year increase of 65.42%. This contributed to the annual value of -$69.4 million for FY2024, which is 33.67% down from last year.
  • Akebia Therapeutics' Net Income towards Common Stockholders amounted to -$69.4 million in FY2024, which was down 33.67% from -$51.9 million recorded in FY2023.
  • Akebia Therapeutics' Net Income towards Common Stockholders' 5-year high stood at -$51.9 million during FY2023, with a 5-year trough of -$384.8 million in FY2020.
  • Over the past 3 years, Akebia Therapeutics' median Net Income towards Common Stockholders value was -$69.4 million (recorded in 2024), while the average stood at -$71.9 million.
  • As far as peak fluctuations go, Akebia Therapeutics' Net Income towards Common Stockholders slumped by 37.61% in 2020, and later surged by 66.59% in 2022.
  • Over the past 5 years, Akebia Therapeutics' Net Income towards Common Stockholders (Yearly) stood at -$384.8 million in 2020, then rose by 26.72% to -$282.0 million in 2021, then spiked by 66.59% to -$94.2 million in 2022, then soared by 44.89% to -$51.9 million in 2023, then crashed by 33.67% to -$69.4 million in 2024.